BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1004 related articles for article (PubMed ID: 31388723)

  • 21. Fibroblast activation protein alpha is expressed by transformed and stromal cells and is associated with mesenchymal features in glioblastoma.
    Busek P; Balaziova E; Matrasova I; Hilser M; Tomas R; Syrucek M; Zemanova Z; Krepela E; Belacek J; Sedo A
    Tumour Biol; 2016 Oct; 37(10):13961-13971. PubMed ID: 27492457
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IDH mutation is paradoxically associated with higher
    Verger A; Metellus P; Sala Q; Colin C; Bialecki E; Taieb D; Chinot O; Figarella-Branger D; Guedj E
    Eur J Nucl Med Mol Imaging; 2017 Aug; 44(8):1306-1311. PubMed ID: 28293705
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A radiohybrid theranostics ligand labeled with fluorine-18 and lutetium-177 for fibroblast activation protein-targeted imaging and radionuclide therapy.
    Yang T; Peng L; Qiu J; He X; Zhang D; Wu R; Liu J; Zhang X; Zha Z
    Eur J Nucl Med Mol Imaging; 2023 Jul; 50(8):2331-2341. PubMed ID: 36864362
    [TBL] [Abstract][Full Text] [Related]  

  • 24. c-Met Expression Is a Useful Marker for Prognosis Prediction in IDH-Mutant Lower-Grade Gliomas and IDH-Wildtype Glioblastomas.
    Ohba S; Yamada Y; Murayama K; Sandika E; Sasaki H; Yamada S; Abe M; Hasegawa M; Hirose Y
    World Neurosurg; 2019 Jun; 126():e1042-e1049. PubMed ID: 30878754
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evans blue-modified radiolabeled fibroblast activation protein inhibitor as long-acting cancer therapeutics.
    Wen X; Xu P; Shi M; Liu J; Zeng X; Zhang Y; Shi C; Li J; Guo Z; Zhang X; Khong PL; Chen X
    Theranostics; 2022; 12(1):422-433. PubMed ID: 34987657
    [No Abstract]   [Full Text] [Related]  

  • 26. Financially effective test algorithm to identify an aggressive, EGFR-amplified variant of IDH-wildtype, lower-grade diffuse glioma.
    Bale TA; Jordan JT; Rapalino O; Ramamurthy N; Jessop N; DeWitt JC; Nardi V; Alvarez MM; Frosch M; Batchelor TT; Louis DN; Iafrate AJ; Cahill DP; Lennerz JK
    Neuro Oncol; 2019 May; 21(5):596-605. PubMed ID: 30496526
    [TBL] [Abstract][Full Text] [Related]  

  • 27.
    Lindner T; Altmann A; Giesel F; Kratochwil C; Kleist C; Krämer S; Mier W; Cardinale J; Kauczor HU; Jäger D; Debus J; Haberkorn U
    EJNMMI Radiopharm Chem; 2021 Aug; 6(1):26. PubMed ID: 34417894
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Mutation of isocitrate dehydrogenase gene in Chinese patients with glioma].
    Pan Y; Qi XL; Wang LM; Dong RF; Zhang M; Zheng DF; Chang Q; Zhong YF
    Zhonghua Bing Li Xue Za Zhi; 2013 May; 42(5):292-8. PubMed ID: 24004584
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of Genetic Profiles and Prognosis of High-Grade Gliomas Using Quantitative and Qualitative MRI Features: A Focus on G3 Gliomas.
    Hong EK; Choi SH; Shin DJ; Jo SW; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH; Park SH; Won JK; Kim TM; Park CK; Kim IH; Lee ST
    Korean J Radiol; 2021 Feb; 22(2):233-242. PubMed ID: 32932560
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preclinical Evaluation and a Pilot Clinical Positron Emission Tomography Imaging Study of [
    Du X; Gu B; Wang X; Wang X; Ji M; Zhang J; He S; Xu X; Yang Z; Song S
    Mol Pharm; 2024 Feb; 21(2):904-915. PubMed ID: 38179677
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular Imaging of Fibroblast Activity After Myocardial Infarction Using a
    Varasteh Z; Mohanta S; Robu S; Braeuer M; Li Y; Omidvari N; Topping G; Sun T; Nekolla SG; Richter A; Weber C; Habenicht A; Haberkorn UA; Weber WA
    J Nucl Med; 2019 Dec; 60(12):1743-1749. PubMed ID: 31405922
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differentiating between glioblastomas with and without isocitrate dehydrogenase gene mutation by findings on conventional magnetic resonance images.
    Shimizu T; Matsushima S; Fukasawa N; Akasaki Y; Mori R; Ojiri H
    J Clin Neurosci; 2020 Jun; 76():140-144. PubMed ID: 32291242
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Peptidic heterodimer-based radiotracer targeting fibroblast activation protein and integrin α
    Liu K; Jiang T; Rao W; Chen B; Yin X; Xu P; Hu S
    Eur J Nucl Med Mol Imaging; 2024 May; 51(6):1544-1557. PubMed ID: 38276986
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular Classification of Gliomas is Associated with Seizure Control: A Retrospective Analysis.
    Easwaran TP; Lancki N; Henriquez M; Vortmeyer AO; Barbaro NM; Scholtens DM; Ahmed AU; Dey M
    Neuromolecular Med; 2021 Jun; 23(2):315-326. PubMed ID: 33206320
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Noninvasive imaging of FAP expression using positron emission tomography: A comparative evaluation of a [
    Huang J; Fu L; Zhang X; Huang S; Dong Y; Hu K; Han Y; Zhou K; Min C; Huang Y; Tang G
    Eur J Nucl Med Mol Imaging; 2023 Sep; 50(11):3363-3374. PubMed ID: 37266596
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preparation and Bioevaluation of
    Ruan Q; Feng J; Jiang Y; Zhang X; Duan X; Wang Q; Yin G; Xiao D; Zhang J
    Mol Pharm; 2022 Jan; 19(1):160-171. PubMed ID: 34904839
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Integrated molecular characterization of IDH-mutant glioblastomas.
    Korshunov A; Casalini B; Chavez L; Hielscher T; Sill M; Ryzhova M; Sharma T; Schrimpf D; Stichel D; Capper D; Reuss DE; Sturm D; Absalyamova O; Golanov A; Lambo S; Bewerunge-Hudler M; Lichter P; Herold-Mende C; Wick W; Pfister SM; Kool M; Jones DTW; von Deimling A; Sahm F
    Neuropathol Appl Neurobiol; 2019 Feb; 45(2):108-118. PubMed ID: 30326163
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA
    Moon ES; Elvas F; Vliegen G; De Lombaerde S; Vangestel C; De Bruycker S; Bracke A; Eppard E; Greifenstein L; Klasen B; Kramer V; Staelens S; De Meester I; Van der Veken P; Rösch F
    EJNMMI Radiopharm Chem; 2020 Jul; 5(1):19. PubMed ID: 32728930
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnostic Performance of [
    Nakajo K; Uda T; Kawashima T; Terakawa Y; Ishibashi K; Tsuyuguchi N; Tanoue Y; Nagahama A; Uda H; Koh S; Sasaki T; Ohata K; Kanemura Y; Goto T
    World Neurosurg; 2021 Apr; 148():e471-e481. PubMed ID: 33444827
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictive role of magnetic resonance imaging in the distinction of isocitrate dehydrogenase (IDH) mutant grade 4 astrocytomas versus glioblastomas.
    Halefoglu AM; Camurcuoglu E; Tanik C; Kizilkaya O; Yilmaz A
    Acta Radiol; 2023 Jun; 64(6):2074-2086. PubMed ID: 37038636
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 51.